BPMC - Blueprint Medicines GAAP EPS of -$2.20 beats by $0.18 revenue of $56.57M beats by $5.92M
2023-10-26 07:11:04 ET
More on Blueprint Medicines
- Blueprint Medicines: Rating Downgrade Amid Growth Concerns
- Blueprint Medicines: At The Forefront Of Groundbreaking Cancer Treatments
- Blueprint Medicines Corporation 2023 Q2 - Results - Earnings Call Presentation
- Blueprint Medicines Q3 2023 Earnings Preview
- Blueprint Medicines dips despite Q2 beat
For further details see:
Blueprint Medicines GAAP EPS of -$2.20 beats by $0.18, revenue of $56.57M beats by $5.92M